Alcon Shares Details of its Scientific Agenda at ESCRS 2021

Alcon Shares Details of its Scientific Agenda at ESCRS 2021

Alcon, the global leader in eye care dedicated to helping people see brilliantly, will share significant data during the 39th Congress of the European Society of Cataract and Refractive Surgery (ESCRS), a hybrid event taking place both virtually and in Amsterdam, Netherlands, from October 8-11.

Three symposia and more than 40 abstracts regarding Alcon ophthalmic products and equipment will be presented, highlighting the company's industry-leading range.

“We are delighted to have the opportunity to connect with our customers at this year’s congress, both in person and virtually for those who cannot attend,” said Stephan Eigenmann, Region Europe VP, Surgical Franchise.

“Alcon, as a historic partner of the ESCRS, will have a significant presence, both on-site in Amsterdam and online, as we believe our innovations and scientific data underline our commitment to our surgeons to deliver optimal outcomes to their patients.”

Alcon will host three educational symposia as part of the official ESCRS scientific program:

1 - The Power of Patient Outcome Data for Sustainable Cataract Care

Friday, 8 October, 3:45-4:30 p.m. CEST

Professor Joaquim Murta from Portugal will moderate the symposium, which will focus on the Importance of Value-Based Healthcare on the European Health Ecosystem.

He will then be joined by Dr. Gareth Roberts from the UK and Professor Antoine Brezin from France, who will speak about transforming care on outcomes insights and real-world data on Nd.YAG laser capsulotomies, respectively.

2 - Embrace the Power of Digital Visualization & Fluid Control in Phaco Procedures

Saturday, 9 October, 3:30-4:15 p.m. CEST

Moderated by Dr. Saleh Al Messabi, he will be joined by Dr. Khalid Al Sabti from Kuwait, Dr. Kjell Gunnar Gundersen from Norway, and Professor Robert Rejdak from Poland to introduce NGENUITY® 3D Visualization System enhancements for both posterior and anterior segments.

They will also present the benefits in terms of safety and efficacy of the ACTIVE SENTRY® Handpiece and INTREPID® Hybrid Tip to anterior segment surgeons and fellows through a series of surgical cases.

Advancing Cataract Refractive Surgery and Presbyopia Correction – Better Outcomes for More Patients

Sunday, 10 October, 11:45 a.m.-12:45 p.m. CEST

Professor Dr. Gerd Auffarth of Germany will moderate this panel, which will include Professor Rudy Nuijts from the Netherlands, Dr. Edoardo Ligabue from Italy, Dr. Ertan Sunay from Turkey, and Dr. Norbert Pesztenlehrer from Hungary.

They will discuss innovative approaches to presbyopia correction with AcrySof® IQ VivityTM, choosing the right advanced technology IOLs, and using the ARGOS® Biometer as a smart planning solution.

More than half of the 41 abstracts will be about Alcon's market-leading intraocular lens technologies, such as AcrySof IQ Vivity and PanOptix® IOLs. These IOLs' optical designs and materials give patients a wide range of alternatives of seeing well, demonstrating Alcon's dedication to innovation.

Reduced Spectacle Dependence and High Patient Satisfaction with AcrySof IQ Vivity IOL is the world's first and only presbyopia-correcting intraocular lens (IOL) with wavefront-shaping technology and a clinically proven low rate of visual disturbances.

Vivity continues to give an extended range of vision while retaining a visual disturbance profile comparable to the best-in-class AcrySof IQ monofocal, according to key data revealed by Alcon.

First interim analysis of the EVOLVE study, a real world, multi-country, ambispective, non-comparative, open-label, non-interventional study/registry conducted in Europe, New Zealand, and Australia, demonstrated:

• 93% and 89% of Vivity patients reported “never” or “rarely” using eyeglasses to see at distance and intermediate in bright light, with the vision of 20/20 at distance, 20/25 at intermediate, and 20/32 at near
• More than 88% of the patients did not report any visual disturbances, halos, glare, or starbursts
• 94.3% of the patients were satisfied with their sight

Presentations will also showcase additional EVOLVE study interim data, including sub-analyses for some particular population cases:

• Patient data from Professor Teus, Dr. Garcia of Spain, and Dr. Gaeckle of Germany
• Patients implanted with Vivity Toric IOL, presented by Dr. Reus of the Netherlands
• Patients with Ocular Comorbidities, presented by Dr. Llovet of Spain
• Patients with Altered Corneas, presented by Dr. Kleineberg of Germany

Additional key presentations on Vivity include:

• Subjective and objective assessment of visual disturbances in patients implanted with three different presbyopia-correcting IOLs, presented by Dr. Guarro
• Clinical outcomes and quality of vision associated with bilateral implantation of a wavefront-shaping presbyopia-correcting intraocular lens after 18 months, presented by Dr. Gundersen
• Predicted optical quality and halos with the Vivity IOL in post-LASIK patients, presented by Dr. Marcos
• A cost-effectiveness analysis of Vivity IOL from Private Health Fund perspective in Australia, presented by Dr. Bala

AcrySof PanOptix Trifocal IOL Provides Excellent Continuous Vision

According to Professor Kohnen, a worldwide pooled analysis of six prospective clinical studies on PanOptix revealed very strong visual performance at all distances under photopic settings in patients of various ethnicities with a full range of vision of 20/25 or better from far to near.

Dr. Lapid-Gortzak will also present that PanOptix IOL provides at least four lines of acuity reserve at 40 and 33 cm.

This novel method to measure the acuity reserve, which demonstrated the superiority of PanOptix to other trifocal IOLs, will be presented in a specific video by Dr. Lapid-Gortzak.

Additional key presentations on PanOptix include:

• Two different studies comparing visual outcomes after implantation of PanOptix compared to two other diffractive trifocal IOLs, presented by Dr. Benyoussef and Dr. Kilic
• IOL comparison study on near vision and spectacle independence in a group of Chinese patients, presented by Dr. Zhang
• A cost-benefit analysis of PanOptix trifocal IOL from patient perspectives in the USA, presented by Dr. Bala

The full abstract book and details of Alcon’s presence are available here.